Health Care·Biotechnology·$185.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.82 | N/A | +10.77% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.82 | N/A | +10.77% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a positive outlook on their product performance. However, they acknowledged potential market challenges ahead.
Management highlighted strong performance in key therapeutic areas.
They expressed confidence in the pipeline but noted challenges in the market.
Amgen's earnings report showed a solid EPS beat, which likely contributed to the stock's 1.84% increase. The positive surprise in EPS reflects strong performance in certain therapeutic areas. However, the lack of revenue details and guidance may leave investors cautious about future growth prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMERICAN ELEC PWR CO
Jan 27, 2014